Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Small Cell Lung Carcinoma 23Breast Neoplasms 17Sarcoma 16Carcinoma, Hepatocellular 10Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Neoplasm Metastasis 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Pheochromocytoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

Imatinib Mesylate 67Sunitinib 27nilotinib 14regorafenib 13ripretinib 10avapritinib 5Ipilimumab 5Dasatinib 5spartalizumab 4Laparoscopy 4CTLA-4 Antigen 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Bevacizumab 3trametinib 2tanespimycin 2ponatinib 2pembrolizumab 2masitinib 2famitinib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Stromal Tumors × anlotinib × Clear all
NCT04106024 2019-09-26

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

Cttq

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡